{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gu S"],"funding":["Innovative Research Group Project of the National Natural Science Foundation of China"],"pagination":["179-192"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12804567"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Introduction
High-dose intravenous methylprednisolone (IVMP) is effective in treating generalized myasthenia gravis (gMG), but early-stage transient aggravation and MG crisis can occur. This study evaluated the safety and efficacy of efgaitigimod in combination with different doses of IVMPs in patients with severe gMG.Methods
This was a single-center, retrospective cohort study that retrospectively collected patients with myasthenia gravis who presented to Hebei Myasthenia Gravis Diagnosis and Treatment Center from December 2023 to May 2024, divided into IVMP monotherapy (1000 mg, Group A, n = 20) or efgartigimod combined with IVMP: 1000 mg (Group B, n = 7), 500 mg (Group C, n = 10), or 250 mg (Group D, n = 20). Patients received efgartigimod (10 mg/kg) intravenously on day"],"journal":["Neurology and therapy"],"pubmed_title":["Efgartigimod Combined with Glucocorticoids in the Treatment of Severe Generalized Myasthenia Gravis: A Single-Center, Retrospective Cohort Study."],"pmcid":["PMC12804567"],"funding_grant_id":["No. 82274582"],"pubmed_authors":["Yang H","Jia P","Li Y","Gu S","Dong H","Ma M","Qi G","Yan C","Wang Y","Li M"],"additional_accession":[]},"is_claimable":false,"name":"Efgartigimod Combined with Glucocorticoids in the Treatment of Severe Generalized Myasthenia Gravis: A Single-Center, Retrospective Cohort Study.","description":"Introduction
High-dose intravenous methylprednisolone (IVMP) is effective in treating generalized myasthenia gravis (gMG), but early-stage transient aggravation and MG crisis can occur. This study evaluated the safety and efficacy of efgaitigimod in combination with different doses of IVMPs in patients with severe gMG.Methods
This was a single-center, retrospective cohort study that retrospectively collected patients with myasthenia gravis who presented to Hebei Myasthenia Gravis Diagnosis and Treatment Center from December 2023 to May 2024, divided into IVMP monotherapy (1000 mg, Group A, n = 20) or efgartigimod combined with IVMP: 1000 mg (Group B, n = 7), 500 mg (Group C, n = 10), or 250 mg (Group D, n = 20). Patients received efgartigimod (10 mg/kg) intravenously on day","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-06-06T14:40:06.893Z","creation":"2026-05-31T03:10:15.248Z"},"accession":"S-EPMC12804567","cross_references":{"pubmed":["41258322"],"doi":["10.1007/s40120-025-00861-4"]}}